Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia
Pediatric Blood & Cancer2020Vol. 68(3), pp. e28888–e28888
Citations Over TimeTop 23% of 2020 papers
Nicole Kucine, Shayla Bergmann, Spencer Krichevsky, Devin E. Jones, Michael Rytting, Juhi Jain, Carolyn M. Bennett, Linda Resar, John Mascarenhas, Srđan Verstovšek, Ronald Hoffman
Abstract
Myeloproliferative neoplasms (MPN) are rare disorders in young patients, and because of this, standardized treatment recommendations are not available. Pediatric patients are more frequently treated with hydroxyurea than interferon, yet there are no data suggesting this is the best practice. Current treatment guidelines for adults suggest using interferon as upfront therapy in young patients. We reviewed the cases of 13 young patients with polycythemia vera or essential thrombocythemia, who were treated with interferon. Extreme thrombocytosis was well controlled and the medication was tolerated by many. Our work shows the need for prospective studies evaluating interferon in our youngest patients with MPN.
Related Papers
- → A clinical update in polycythemia vera and essential thrombocythemia(2000)115 cited
- → Anagrelide for thrombocytosis in myeloproliferative disorders(2004)78 cited
- → New drugs in essential thrombocythemia and polycythemia vera(1997)37 cited
- → Thrombocytosis in young people: Evaluation of 57 cases diagnosed before the age of 40(1990)31 cited
- 6-Thioguanine treatment of uncontrolled thrombocytosis in polycythemia vera and essential thrombocythemia.(1985)